Spectranetics CVX-300
This article was originally published in The Gray Sheet
Executive Summary
Excimer laser coronary angioplasty system gains expanded FDA approval for use within stents prior to brachytherapy - a market potential estimated at $50 mil. Clinical trials to treat circulatory problems in the legs are ongoing and represent a $400-600 mil. opportunity, firm says. Company reports a 13% advance in third-quarter revenue to $7.2 mil. on Oct. 17. Net income of $522,000 compares to a loss of $4.6 mil. for the comparable quarter a year ago
You may also be interested in...
Expanded CVX-300 Claims Are Spectranetics CEO’s First Order Of Business
Incoming Spectranetics President/CEO John Schulte is pledging to fulfill the company's strategic goal to expand indications for the CVX-300 excimer laser, starting with critical limb (lower leg) ischemia
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.